NIS2 in the health sector

Affec­ted enti­ties and demar­ca­ti­on issues

Enti­ties that fall under the Ger­man BSI Act (BSIG), the Ger­man imple­men­ta­ti­on of the NIS2 Direc­ti­ve (Direc­ti­ve (EU) 2022/2555), must regis­ter on the por­tal of the Fede­ral Office for Infor­ma­ti­on Secu­ri­ty (BSI) by March 6, 2026. Howe­ver, it is esti­ma­ted that only around 5,000 to 6,000 enti­ties regis­tered by the dead­line, which is signi­fi­cant­ly fewer than the num­ber of enti­ties expec­ted to be affec­ted. Many enti­ties have encoun­te­red uncer­tain­ties and demar­ca­ti­on issues when asses­sing their level of invol­vement, which has led to delays. This is par­ti­cu­lar­ly the case in the health sector.

Despi­te the types of enti­ties lis­ted in Anne­xes 1 and 2 of the BSIG, uncer­tain­ty often ari­ses in prac­ti­ce. This is pri­ma­ri­ly due to vague wor­ding, a lack of defi­ni­ti­ons for key terms and num­e­rous refe­ren­ces to other Euro­pean and natio­nal legal acts. In the health sec­tor, enti­ties often must con­sider seve­ral sets of regu­la­ti­ons to deter­mi­ne whe­ther they are sub­ject to the BSIG.

Health­ca­re providers

Annex 1 No. 4 BSIG in the sec­tor “Health” covers health­ca­re pro­vi­ders. The law refers to the Pati­ent Mobi­li­ty Direc­ti­ve (Direc­ti­ve 2011/24/EU). Accor­ding to Artic­le 3(g) of this Direc­ti­ve, a health­ca­re pro­vi­der is any natu­ral or legal per­son or any other enti­ty legal­ly pro­vi­ding health­ca­re […]. Health­ca­re means health ser­vices pro­vi­ded by health pro­fes­sio­nals to pati­ents to assess, main­tain or res­to­re their sta­te of health, inclu­ding the pre­scrip­ti­on, dis­pen­sa­ti­on and pro­vi­si­on of medi­cinal pro­ducts and medi­cal devices (Art. 3(a)).

The term is broad­ly defi­ned, cove­ring much more than just hos­pi­tals and doc­tors’ offices. It is pre­cis­e­ly this broad wor­ding, tog­e­ther with the BSI­G’s refe­rence to the Pati­ent Mobi­li­ty Direc­ti­ve, that gives rise to ques­ti­ons of demar­ca­ti­on in prac­ti­ce. For exam­p­le, this is the case with emer­gen­cy ser­vices and care services.

Emer­gen­cy services

In prac­ti­ce, the­re has recent­ly been inten­se deba­te as to whe­ther emer­gen­cy ser­vices are con­side­red health­ca­re pro­vi­ders. This was trig­ge­red by infor­ma­ti­on from the BSI, which initi­al­ly did not clas­si­fy emer­gen­cy ser­vices as such. The BSI has sin­ce revi­sed this assess­ment and now clas­si­fies emer­gen­cy ser­vices as health­ca­re pro­vi­ders within the mea­ning of the BSIG.

In view of the pur­po­se of the BSIG and the broad defi­ni­ti­on of health­ca­re, the out­co­me may seem under­stan­da­ble. Howe­ver, as Ste­fan Hes­sel explains, the legal basis for this remains unclear. The Court of Jus­ti­ce of the Euro­pean Uni­on (CJEU) alre­a­dy ruled in 2019 that emer­gen­cy ser­vices and qua­li­fied pati­ent trans­port are to be clas­si­fied as hazard pre­ven­ti­on and thus public secu­ri­ty (CJEU, judgment of June 27, 2019 – C‑465/17). Howe­ver, Art. 2(7) of the NIS2 Direc­ti­ve con­ta­ins an expli­cit exemp­ti­on from the scope of appli­ca­ti­on for acti­vi­ties in the field of public secu­ri­ty. Against this back­ground, it remains to be explai­ned why the BSI now clas­si­fies emer­gen­cy ser­vices as part of the health sec­tor and thus includes them in the scope of the BSIG.

Care ser­vices

When it comes to care ser­vices, it is important to distin­gu­ish bet­ween short-term and long-term care. Long-term care is excluded from the scope of the BSIG. The Pati­ent Mobi­li­ty Direc­ti­ve con­ta­ins a cor­re­spon­ding exemp­ti­on for ser­vices that assist indi­vi­du­als in car­ry­ing out rou­ti­ne, ever­y­day tasks. The expl­ana­to­ry memo­ran­dum to the BSIG also sta­tes that long-term care faci­li­ties are not con­side­red to be health­ca­re pro­vi­ders under the law.

Some quar­ters have deba­ted this excep­ti­on dog­ma­ti­cal­ly, as the NIS2 Direc­ti­ve its­elf con­ta­ins no excep­ti­on for long-term care and makes no refe­rence to the excep­ti­on in the Pati­ent Mobi­li­ty Direc­ti­ve. Howe­ver, the Euro­pean Com­mis­si­on’s cur­rent pro­po­sal to amend the NIS2 Direc­ti­ve, which expli­cit­ly excludes long-term care, sup­ports this interpretation.

In prac­ti­ce, this rai­ses the ques­ti­on of how to distin­gu­ish bet­ween long-term and short-term care. This is deter­mi­ned on a func­tion­al basis: long-term care pri­ma­ri­ly invol­ves assis­ting with dai­ly acti­vi­ties, whe­re­as the medi­cal tre­at­ment falls under the cate­go­ry of health ser­vices. The­re is no bin­ding time thres­hold for the term “long-term care” under EU law. Howe­ver, in prac­ti­ce, it may be appro­pria­te to refer to Sec­tions 14(1) and 2(1) of the Ele­venth Book of the Ger­man Social Code (SGB XI) and the Ninth Book of the Ger­man Social Code (SGB IX) (six months).

Manu­fac­tu­r­ers of medi­cal devices and IVD

In the sec­tor “Manu­fac­tu­ring”, par­ti­cu­lar­ly among manu­fac­tu­r­ers of medi­cal devices and in vitro dia­gno­stic medi­cal devices (IVD) (Annex 2 No. 5 BSIG), ques­ti­ons of demar­ca­ti­on ari­se in prac­ti­ce. This par­ti­cu­lar­ly appli­es to com­pa­nies that do not manu­fac­tu­re pro­ducts them­sel­ves but ins­tead have them manu­fac­tu­red and then repacka­ge and dis­tri­bu­te them under their own name.

Neither the BSIG nor the NIS2 Direc­ti­ve con­ta­ins its own defi­ni­ti­on of “manu­fac­tu­rer”. Like the Direc­ti­ve, the BSIG refers to the Medi­cal Devices Regu­la­ti­on (MDR) and the In Vitro Dia­gno­stic Medi­cal Devices Regu­la­ti­on (IVDR). Accor­ding to the­se pro­duct laws, a manu­fac­tu­rer is defi­ned as a natu­ral or legal per­son who manu­fac­tures or ful­ly refur­bis­hes a device or has a device desi­gned, manu­fac­tu­red or ful­ly refur­bis­hed, and mar­kets that device under its name or trade­mark. The focus is the­r­e­fo­re on mar­ket respon­si­bi­li­ty for the pro­duct rather than on the ope­ra­tio­nal pro­duc­tion pro­cess its­elf. This defi­ni­ti­on is con­sis­tent with the prin­ci­ples of pro­duct (safe­ty) law.

Howe­ver, the NIS2 regu­la­ti­on aims to ensu­re the cyber­se­cu­ri­ty of cri­ti­cal enti­ties. The­r­e­fo­re, the cri­ti­cal­i­ty of the enti­ty and its ope­ra­tio­nal pro­ces­ses is par­ti­cu­lar­ly important. Addi­tio­nal­ly, NIS2 refers to various Euro­pean regu­la­ti­ons that employ dif­fe­rent defi­ni­ti­ons of “manu­fac­tu­rer”. For ins­tance, the REACH Regu­la­ti­on and the NACE clas­si­fi­ca­ti­on sys­tem are lin­ked to the manu­fac­tu­ring pro­cess its­elf. The­r­e­fo­re, the lite­ra­tu­re (inclu­ding Hessel/Schneider, MMR 2025, 243) empha­si­zes that the Euro­pean legis­la­tor did not intend to use an incon­sis­tent defi­ni­ti­on of “manu­fac­tu­rer”. Ins­tead, a defi­ni­ti­on of “manu­fac­tu­rer” rela­ted to cyber­se­cu­ri­ty should be used. Accor­ding to this defi­ni­ti­on, the manu­fac­tu­rer under NIS2 as well as the BSIG is the par­ty that car­ri­es out the ope­ra­tio­nal manu­fac­tu­ring process.

Con­clu­si­on

The impact assess­ment under NIS2 / BSIG remains com­plex, par­ti­cu­lar­ly in the health sec­tor. Vague ter­mi­no­lo­gy, num­e­rous refe­ren­ces to other EU regu­la­ti­ons and con­flic­ting regu­la­to­ry objec­ti­ves mean that it is often impos­si­ble to clas­si­fy indi­vi­du­al insti­tu­ti­ons at first glance.

In prac­ti­ce, this means that enti­ties should not sole­ly base their level of invol­vement on for­mal cate­go­ries, but also on their spe­ci­fic acti­vi­ties and func­tion­al role in the health sec­tor. Dif­fe­ren­tia­ted clas­si­fi­ca­ti­on is espe­ci­al­ly important in bor­der­line are­as. The clas­si­fi­ca­ti­on is com­plex and the imple­men­ta­ti­on pro­cess is chal­len­ging and time cri­ti­cal. If you have any ques­ti­ons or requi­re assis­tance with imple­men­ting NIS2, plea­se do not hesi­ta­te to cont­act us.

Check now if your com­pa­ny is affec­ted by NIS2 with our free NIS2 Quick-Check.

back

Stay up-to-date

We use your email address exclusively for sending our newsletter. You have the right to revoke your consent at any time with effect for the future. For further information, please refer to our privacy policy.